The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like ...

Tevimbra is currently approved in the EU as a treatment for gastric cancer, esophageal squamous cell cancer and small cell ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

Air pollution in India linked to rising lung cancer cases, emphasizing the urgent need for research and action.

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...